Everstar Asset Management LLC Has $770,000 Stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST)

Everstar Asset Management LLC cut its holdings in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) by 46.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 216,223 shares of the company's stock after selling 183,902 shares during the quarter. Everstar Asset Management LLC owned about 0.24% of Aquestive Therapeutics worth $770,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of AQST. New York State Common Retirement Fund grew its position in Aquestive Therapeutics by 713.3% in the 4th quarter. New York State Common Retirement Fund now owns 12,200 shares of the company's stock worth $43,000 after purchasing an additional 10,700 shares during the last quarter. PKS Advisory Services LLC bought a new stake in shares of Aquestive Therapeutics in the fourth quarter valued at about $63,000. China Universal Asset Management Co. Ltd. acquired a new stake in Aquestive Therapeutics during the fourth quarter worth about $69,000. Intech Investment Management LLC bought a new position in Aquestive Therapeutics during the third quarter valued at about $90,000. Finally, BNP Paribas Financial Markets raised its holdings in Aquestive Therapeutics by 252.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 18,826 shares of the company's stock valued at $94,000 after acquiring an additional 13,481 shares in the last quarter. 32.45% of the stock is owned by institutional investors.

Aquestive Therapeutics Price Performance

Shares of NASDAQ AQST traded down $0.16 during midday trading on Friday, reaching $2.71. 1,306,279 shares of the stock were exchanged, compared to its average volume of 1,588,600. Aquestive Therapeutics, Inc. has a 12 month low of $2.24 and a 12 month high of $5.80. The business has a 50-day simple moving average of $2.97 and a two-hundred day simple moving average of $3.89. The company has a market capitalization of $267.94 million, a price-to-earnings ratio of -6.02 and a beta of 2.59.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last posted its earnings results on Wednesday, March 5th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.05). The business had revenue of $11.87 million during the quarter, compared to analysts' expectations of $13.11 million. Equities research analysts expect that Aquestive Therapeutics, Inc. will post -0.46 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on AQST. Cantor Fitzgerald assumed coverage on Aquestive Therapeutics in a research report on Tuesday, December 17th. They set an "overweight" rating and a $17.00 price objective on the stock. Lake Street Capital lowered their price target on shares of Aquestive Therapeutics from $10.00 to $8.00 and set a "buy" rating on the stock in a report on Friday, March 7th. HC Wainwright reaffirmed a "buy" rating and set a $10.00 price objective on shares of Aquestive Therapeutics in a report on Wednesday. Alliance Global Partners reissued a "buy" rating on shares of Aquestive Therapeutics in a research note on Friday, March 7th. Finally, Raymond James set a $7.00 price target on shares of Aquestive Therapeutics in a research note on Friday, March 7th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $10.57.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.